MedTrace Logo

Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker)

NCT03386266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2026-05-06

No results posted yet for this study

Summary

CMT is a rare disease for which novel treatments are being developed. Evaluation of intervention efficacy is hampered by slow progression and lack of sensitive outcome measures. Primary goal of the project is to identify and validate RNA and protein derived biomarkers in blood of CMT patients for selected outcome measures over 2 years. The investigators expect to develop more responsive outcome measures and circulating biomarkers to improve assessment of intervention efficacy in forthcoming therapeutic trials.

Conditions

  • Charcot-Marie-Tooth Disease, Type IA

Sponsors & Collaborators

  • University Hospital Muenster

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • University Medical Center Goettingen

    lead OTHER

Principal Investigators

  • Michael W. Sereda, MD, Professor of Neurology · University Medical Center Goettingen

Eligibility

Min Age
3 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-11
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03386266 on ClinicalTrials.gov